Enthralling Transformation of Pain Medication into a Cancer Eradicator
Since long scientists have failed to pinpoint the precise reason behind lesser occurrences of particular cancer forms among regular NSAID users such as aspirin. Presently, study researchers from Sanford-Burnham have finally managed to crack this code and decode just how one non-steroidal anti-inflammatory drug (NSAID) Sulindac hinders tumor development.
The research has shown that pain medication Sulindac puts a halt to cancerous cell development and has been found to initiate cell fatality by attaching to the RXRα nuclear receptor, a protein type which on receipt of signal would carry it inside the nucleus for turning genes on/off.
The lead researcher in this study, Xiao-kun Zhang, Prof. from Sanford-Burnham stated that 13% of existent medications have been found to be targeting nuclear receptors even despite the means of action not being mostly apparent.
RXRα usually has been found to suppress tumor types, however several kinds of cancerous cells are capable of producing a condensed version of the RXRα nuclear receptor which appears to be doing merely the contrary. This research reveals that abridged RXRα nuclear receptor improves tumor development by triggering other protein types which assist cancerous cells in surviving. Providentially, the study investigators additionally noted the NSAID Sulindac could be employed for combating this nonstandard RXRα nuclear receptor by turning off its survival-favouring role and switching on programmed cell death or apoptosis (process which notifies cells in destructing themselves).
Sulindac is presently a prescription pain medication that helps in allaying aches and fever and for relieving arthritis signs and symptoms. The present research has illustrated a new-fangled function for this NSAID as a likely cancer-combatant therapy which is capable of targeting pruned RXRα protein present in tumor forms. But, regrettably, a number of NSAIDs have received excessive negative publicity due to their likely detrimental heart side-effects. For overcoming this restraint, the investigators have nipped Sulindac and developed a novel type of medication, presently known as K-80003 which could decrease unfavourable effects as well as increase fastening to condensed RXRα.
Dr. Zhang further explicated that based on the circumstances; the analogous protein like RXRα could obliterate cancerous cells or encourage their development. He mentioned that adding K-80003 had been observed to shift the equilibrium by obstructing survival paths and making the cancerous cells more sensitive to elicitors of programmable cell death.
One of the most horrific things about present medicine is that most people with cancer, even with mild pain, are treated with morphine in some form. One morphine injection can already be fatal if given during the critical EC [‘Epileptic Crises’].
It changes the brain, paralyzes the intestines and completely disables the restoration functions, well, disables the whole person.
He becomes lethargic and doesn’t realize that he’s in fact being killed, just when he was in the recuperation phase, on his way to health.
The pain of the second stage is actually a very good sign of recovery, but modern medicine doesn’t understand this at all, and instead interprets it as the opposite; a sign of impending death.
These substances are thus administered in order to ‘make the end easier’, and sure enough, the person soon dies, but it’s not of the cancer, it’s of the medication…”